An increase in prostate cancer diagnosis during inflammatory bowel disease: A systematic review and meta-analysis

Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):302-309. doi: 10.1016/j.clinre.2019.07.003. Epub 2019 Aug 23.

Abstract

Background: In recent years, some studies showed that inflammatory bowel disease (IBD) might be associated with an increased risk of prostate cancer (PC), whereas some other studies indicated that IBD was not associated with the increased risk of PC. In the present study, we aimed to conduct a systematic review and meta-analysis to evaluate the association of IBD and PC risk.

Methods: Web of Science and PubMed were systematically searched on for link of PC risk and IBD published from January 1976 to February 2019. The pooled multivariate odd ratio (OR) or relative risk (RR) and 95% confidence intervals (CI) were obtained by the use of STATA 12.0 software.

Results: The meta-analysis indicated that IBD showed a 78% increase in PC risk (95% CI: 1.32-2.41). Sensitivity analyses showed no changes in the direction of effect after excluding any one study (supplementary figure 1). A significant heterogeneity was detected between different studies (Q test, P<0.001). Moreover, Begg's test, Egger's tests and funnel plots indicated no significant publication bias between included studies [Begg's test (P=0.371); Egger's test (p=0.100)].

Conclusion: The present meta-analysis demonstrated that IBD was associated with an increased diagnosis of PC. In addition, large scale prospective studies are essential to determine whether IBD increase the PC risk.

Keywords: Inflammatory bowel disease; Meta-analysis; Prostate cancer.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Confidence Intervals
  • Humans
  • Inflammatory Bowel Diseases / complications*
  • Male
  • Odds Ratio
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / epidemiology
  • Prostatic Neoplasms / etiology
  • Publication Bias
  • Risk